Do Clinical Pathways Inhibit Cancer Care?
Clinical pathways could be the route to less transparent, more restricted cancer care.
Physicians Urge Protection for Cancer Care in New IfPA White Paper
Once upon a time, the gravity of cancer ensured its patients access to life-saving treatments.
Cancer Cost-shifting Provokes Discrimination Complaints
Exchange insurance plans may make second-class citizens of patients with chronic disease, a recent Peter Pitts commentary contends.
Cost, Quality Debates Dominate Cancer Policy Workshop
How do we go about ”Ensuring Patient Access to Cancer Drugs”? Ethicists, economists, physicians and academics gathered for the Institute of Medicine’s National Cancer Policy Forum Workshop this week to discuss the topic.
‘My Life is Worth It’ Voices Cancer Patients’ Concerns
The value of innovative cancer treatments – both in dollars and cents and in human life – takes center stage this month with two complementary efforts to encourage pro-patient policy.
Cancer Care Access Threatened by Payment Disparity
Data suggests the costs of chemotherapy may vary dramatically depending on the care setting.
High Co-Pays Inhibit Access for Cancer Patients
You can’t put a price on health, the saying goes. But for certain leukemia patients who need protein kinase inhibitor treatment, cost can prove to be not only a key factor but also a barrier to wellness.
